RICHARD KOTOMORI: Open Payments
NPI 1215059084 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,397 in 181 payments from 22 companies in 2025. Trend: 2023 $2,984 · 2024 $2,531 · 2025 $3,397
Food & beverage: $3,397
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 28 | $596 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $312 |
| Alkermes, Inc. | 18 | $310 |
| Vanda Pharmaceuticals Inc. | 17 | $289 |
| Collegium Pharmaceutical, Inc. | 17 | $239 |
| E.R. Squibb & Sons, L.L.C. | 16 | $227 |
| ABBVIE INC. | 9 | $203 |
| Otsuka America Pharmaceutical, Inc. | 9 | $180 |
| Tris Pharma Inc | 10 | $167 |
| Axsome Therapeutics, Inc. | 7 | $156 |
Products named: INGREZZA, CAPLYTA, ARISTADA, Jornay PM, COBENFY, REXULTI, VRAYLAR, HETLIOZ.
Industry payments across CA — which companies pay providers there.
